Switzerland-based Myovant announced an 88 percent one-year response rate in the positive Phase III LIBERTY extension study of once-daily, oral relugolix combination therapy in women with heavy menstrual bleeding associated with uterine fibroids.

The European Commission granted marketing authorization to Amgen and UCB for Evenity (romosozumab) for treating severe osteoporosis in postmenopausal women at high risk of fracture.

The U.S. FDA approved a bone-building drug from Pfenex Inc. to treat osteoporosis in certain patients at high risk for fractures, marking the company’s first commercial product.

People who track their daily steps may not only be more active, they may also be less likely to develop health problems that lead to events like heart attacks or broken bones, a new study suggests.

Amgen Inc. set the U.S. list price for the company’s new Evenity osteoporosis drug at $1,825 a month, or $21,900 for a full 12-month course of injections.

Amgen and UCB announced that the U.S. FDA approved Evenity (romosozumab-aqqg) for the treatment of osteoporosis in postmenopausal women at high risk for fracture.

The EMA’s risk assessment committee recommended restrictions on the use of the broad-spectrum antibiotics.

Decreasing sensitivity to insulin — often associated with obesity and eventual type 2 diabetes — may also cause young adults to have lower bone mass at a time of life when it should be at its peak, Korean researchers say.

A federal jury in Dallas ordered Johnson & Johnson and its DePuy Orthopaedics unit to pay more than $1 billion to six plaintiffs who said they were injured by Pinnacle hip implants.

Concerted effort by governments, regulators, and industry is rapidly expanding development of new therapies for the more than 7,000 known rare diseases.